Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06443359 · ClinicalTrials.gov registry record · NA

Hypofractionated Regional Nodal Irradiation in Breast Cancer

A NA study of Breast Cancer, sponsored by Corewell Health East.

Active
Registry status
NA
Development phase
56
Enrollment target
3
Study locations

NCT06443359 is a NA study of Breast Cancer that is active but no longer recruiting, run by Corewell Health East. The registered enrollment target is 56 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06443359, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Corewell Health East.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
56 participants
Enrollment target
3
Study locations

Study Summary

This is a prospective clinical trial designed to evaluate the efficacy and safety of hypofractionated regional nodal irradiation in breast cancer patients. After enrollment, participants will be stratified into 2 Groups based on the extent of axillary surgery. Participants will complete activities and assessments at baseline, and after completion of treatment at 1-2 weeks, 3 months, 6 months, 1 year, 2 year, and 3 years following completion of treatment.

Conditions Studied

Interventions

  • RADIATION hypofractionated radiation

Study Locations (3)

Michigan

  • Corewell Health Dearborn Hospital - Dearborn
  • Corewell Health William Beaumont University Hospital - Royal Oak
  • Corewell Health Beaumont Troy Hospital - Troy

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2018-11-13
Est. Completion 2027-07
Phase NA

Sponsor

Corewell Health East

106 total trials

What the Registry Record Tells You About NCT06443359

The ClinicalTrials.gov registry entry for NCT06443359 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which hypofractionated radiation is the first listed.

NCT06443359 reports 3 study locations spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT06443359 about?

NCT06443359 is a clinical study titled "Hypofractionated Regional Nodal Irradiation in Breast Cancer". This is a prospective clinical trial designed to evaluate the efficacy and safety of hypofractionated regional nodal irradiation in breast cancer patients. After enrollment, participants will be stratified into 2 Groups based on the extent of axillary surgery. Participants will complete activities a...

What is the current status of trial NCT06443359?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2018-11-13. Estimated completion is 2027-07.

What conditions does trial NCT06443359 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT06443359?

The interventions under investigation include: hypofractionated radiation (RADIATION).

Who is sponsoring clinical trial NCT06443359?

This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06443359 being conducted?

This trial has 3 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.